Nancy Joann Johnson Sells 10,582 Shares of Billiontoone (NASDAQ:BLLN) Stock

Billiontoone, Inc. (NASDAQ:BLLN) insider Nancy Joann Johnson sold 10,582 shares of the company’s stock in a transaction that occurred on Tuesday, June 9th. The shares were sold at an average price of $100.47, for a total transaction of $1,063,173.54. Following the completion of the transaction, the insider owned 21,900 shares of the company’s stock, valued at approximately $2,200,293. This trade represents a 32.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Nancy Joann Johnson also recently made the following trade(s):

• On Monday, June 8th, Nancy Joann Johnson sold 3,418 shares of Billiontoone stock. The shares were sold at an average price of $99.28, for a total transaction of $339,339.04.

Billiontoone Price Performance

Shares of NASDAQ:BLLN opened at $99.30 on Friday. The firm has a market cap of $4.57 billion and a PE ratio of 180.55. The firm’s fifty day moving average is $87.67 and its 200-day moving average is $88.10. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.58 and a current ratio of 10.92. Billiontoone, Inc. has a 52 week low of $61.96 and a 52 week high of $138.70.

Billiontoone (NASDAQ:BLLN) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.34 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.33. The company had revenue of $108.39 million during the quarter, compared to analyst estimates of $95.81 million. The business’s revenue for the quarter was up 83.8% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.39) earnings per share. Sell-side analysts predict that Billiontoone, Inc. will post 0.93 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Guggenheim lifted their price objective on Billiontoone from $100.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday, May 13th. BTIG Research lowered their price target on shares of Billiontoone from $140.00 to $130.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Wells Fargo & Company decreased their price objective on shares of Billiontoone from $110.00 to $90.00 and set an “equal weight” rating for the company in a research report on Thursday, March 5th. Weiss Ratings lowered shares of Billiontoone from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, June 5th. Finally, JPMorgan Chase & Co. upped their price target on shares of Billiontoone from $120.00 to $125.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Six analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $125.29.

Hedge Funds Weigh In On Billiontoone

Institutional investors and hedge funds have recently modified their holdings of the business. Rossby Financial LCC bought a new stake in shares of Billiontoone in the 4th quarter valued at $25,000. Wells Fargo & Company MN bought a new position in Billiontoone during the fourth quarter worth $76,000. Smartleaf Asset Management LLC bought a new stake in Billiontoone in the fourth quarter valued at $80,000. Nano Cap New Millennium Growth Fund L P acquired a new position in shares of Billiontoone during the fourth quarter valued at about $82,000. Finally, Renaissance Capital LLC bought a new position in shares of Billiontoone during the 4th quarter worth about $201,000.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.